SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron

References

• Kuzmina A, Khalaila Y, Voloshin O, et al. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. Cell Host Microbe. 2021;29:522–528 e522.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Arora P, Gross R, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021;184:2384–2393 e2312.
   PubMed Web of Science ®Google Scholar
• Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184:2372–2383 e2379.
   PubMed Web of Science ®Google Scholar
• Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature. 2021;600:21.
   PubMed Web of Science ®Google Scholar
• He X, Hong W, Pan X, et al. SARS-CoV-2 Omicron variant: characteristics and prevention. MedComm. 2021;8:838–845.
   Google Scholar
• Guo Y, Han J, Zhang Y, et al. SARS-CoV-2 Omicron variant: epidemiological features, biological characteristics, and clinical significance. Front Immunol. 2022;13:877101.
   PubMed Web of Science ®Google Scholar
• Markov PV, Katzourakis A, Stilianakis NI. Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity. Nat Rev Microbiol. 2022;20:251–252.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263.
   PubMed Web of Science ®Google Scholar
• Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and Antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281–292 e286.
   PubMed Web of Science ®Google Scholar
• Tang T, Bidon M, Jaimes JA, et al. Coronavirus membrane fusion mechanism offers a potential target for antiviral development. Antiviral Res. 2020;178:104792.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yu D, Yan H, et al. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity. J Virol. 2020;94:e00635-20.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yu D, Hu Y, et al. SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. Signal Transduct Target Ther. 2021;6:294.
   PubMed Web of Science ®Google Scholar
• Yu D, Zhu Y, Jiao T, et al. Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. Emerg Microbes Infect. 2021;10:1227–1240.
   PubMed Web of Science ®Google Scholar
• Yu D, Zhu Y, Yan H, et al. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus. Emerg Microbes Infect. 2021;10:810–821.
   PubMed Web of Science ®Google Scholar
• Tao K, Tzou PL, Nouhin J, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. 2021;22:757–773.
   PubMed Web of Science ®Google Scholar
• Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med. 2021;27:917–924.
   PubMed Web of Science ®Google Scholar
• Li Q, Nie J, Wu J, et al. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell. 2021;184:2362–2371 e2369.
   PubMed Web of Science ®Google Scholar
• Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593:130–135.
   PubMed Web of Science ®Google Scholar
• Fan Y, Li X, Zhang L, et al. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022;7:141.
   PubMed Web of Science ®Google Scholar
• Zhao H, Lu L, Peng Z, et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect. 2022;11:277–283.
   PubMed Web of Science ®Google Scholar
• Uraki R, Kiso M, Iida S, et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2. Nature. 2022;607:119–127.
   PubMed Web of Science ®Google Scholar
• Yamasoba D, Kimura I, Nasser H, et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. Cell. 2022;185:2103–2115 e2119.
   PubMed Web of Science ®Google Scholar
• Li Q, Wu J, Nie J, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182:1284–1294 e1289.
   PubMed Web of Science ®Google Scholar
• Saito A, Irie T, Suzuki R, et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature. 2022;602:300–306.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xiao T, Cai Y, et al. Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant. Science. 2021;374:1353–1360.
   PubMed Web of Science ®Google Scholar
• Zeng C, Evans JP, King T, et al. SARS-CoV-2 spreads through cell-to-cell transmission. Proc Natl Acad Sci U S A. 2022;119:e2111400119.
   PubMed Web of Science ®Google Scholar
• Xue J, Chong H, Zhu Y, et al. Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide. Cell. 2022;185:131–144 e118.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Chong H, Yu D, et al. Design and characterization of cholesterylated peptide HIV-1/2 fusion inhibitors with extremely potent and long-lasting antiviral activity. J Virol. 2019;93:e02312-18.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang X, Ding X, et al. Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus. J Biol Chem. 2018;293:5323–5334.
   PubMed Web of Science ®Google Scholar
• Chong H, Zhu Y, Yu D, et al. Structural and functional characterization of membrane fusion inhibitors with extremely potent activity against HIV-1, HIV-2, and simian immunodeficiency virus. J Virol. 2018;92:e01088-18.
   PubMed Web of Science ®Google Scholar
• Chong H, Xue J, Zhu Y, et al. Design of novel HIV-1/2 fusion inhibitors with high therapeutic efficacy in rhesus monkey models. J Virol. 2018;92:e00775-18.
   PubMed Web of Science ®Google Scholar
• Ding X, Zhang X, Chong H, et al. Enfuvirtide (T20)-based lipopeptide is a potent HIV-1 cell fusion inhibitor: implication for viral entry and inhibition. J Virol. 2017;91:e00831-17.
   PubMed Web of Science ®Google Scholar
• Chong H, Xue J, Xiong S, et al. A lipopeptide HIV-1/2 fusion inhibitor with highly potent in vitro, ex vivo, and in vivo antiviral activity. J Virol. 2017;91:e00288-17.
   PubMed Web of Science ®Google Scholar
• Chong H, Wu X, Su Y, et al. Development of potent and long-acting HIV-1 fusion inhibitors. AIDS. 2016;30:1187–1196.
   PubMed Web of Science ®Google Scholar
• Chong H, Xue J, Zhu Y, et al. Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques. PLoS Pathog. 2019;15:e1007552.
   PubMed Web of Science ®Google Scholar
• de Vries RD, Schmitz KS, Bovier FT, et al. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets. Science. 2021;371:1379–1382.
   PubMed Web of Science ®Google Scholar
• Outlaw VK, Bovier FT, Mears MC, et al. Inhibition of coronavirus entry in vitro and ex vivo by a lipid-conjugated peptide derived from the SARS-CoV-2 Spike Glycoprotein HRC domain. mBio. 2020;11:e01935-20.
   PubMed Web of Science ®Google Scholar
• Xia S, Chan JF, Wang L, et al. Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. Cell Res. 2022;32:404–406.
   PubMed Web of Science ®Google Scholar
• Lan Q, Chan JF, Xu W, et al. A palmitic acid-conjugated, peptide-based pan-CoV fusion inhibitor potently inhibits infection of SARS-CoV-2 Omicron and other variants of concern. Viruses. 2022;14:549.
   PubMed Web of Science ®Google Scholar